Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Risperidone, Olanzapine Clear all
Terminated Phase 2Phase 3 Interventional

A Long-Term, Open-Label, Study on Schizophrenia

NCT01129674
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 1 Interventional

Movement Disorders Caused by Antipsychotic Drugs in Older Patients

NCT00255879
View directory record Official record
Conditions
Dyskinesia, Drug-Induced
Interventions
Quetiapine, Risperidone, Olanzapine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

NCT05402111
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 3 Interventional

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

NCT00347425
View directory record Official record
Conditions
Schizophrenia and Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
63
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 21, 2008 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Janssen - Glucose Regulation/Risp/Olanz

NCT00205738
View directory record Official record
Conditions
Schizophrenia, Type 2 Diabetes Mellitus
Interventions
Risperidone, Olanzapine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 2Phase 3 Interventional

Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia

NCT00235352
View directory record Official record
Conditions
Schizophrenia
Interventions
CX516 (Ampakine)
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2009 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 4 Interventional Results available

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

NCT00330863
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 2, 2026, 1:01 AM EDT
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (New Use) Weight Loss Study

NCT01272752
View directory record Official record
Conditions
Obesity
Interventions
IHBG-10, Placebo
Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 4 Interventional Results available

Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

NCT00338949
View directory record Official record
Conditions
Schizophrenia, Metabolic Syndrome X, Insulin Resistance
Interventions
Switch, Control
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Not applicable Interventional

Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder

NCT00179062
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
Interventions
olanzapine versus risperidone
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2008 · Synced Oct 2, 2026, 1:01 AM EDT
Completed No phase listed Observational

A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

NCT04002700
View directory record Official record
Conditions
Stroke
Interventions
Haloperidol, Typical Antipsychotics, Atypical Antipsychotics
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,234,412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 2, 2026, 1:01 AM EDT
Not yet recruiting Not applicable Interventional

Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area

NCT07570875
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ketogenic foodstuffs, Standard of Care Oral antipsychotics, Standard of care long acting injectable medication for bipolar disorder
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Montgomery, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 2, 2026, 1:01 AM EDT
Recruiting No phase listed Observational

Maternal And Infant Antipsychotic Study

NCT06049953
View directory record Official record
Conditions
Antipsychotics, Pregnancy
Interventions
Antipsychotics, Non-antipsychotic medication, No Medication
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI

NCT01234454
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Olanzapine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 1 Interventional

Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

NCT01231074
View directory record Official record
Conditions
Obesity, Weight Gain, Psychotropic Induced Weight Gain
Interventions
Metformin
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

NCT03557931
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
27
States / cities
Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 4 Interventional Results available

Metabolic Effects of Antipsychotics in Children

NCT00205699
View directory record Official record
Conditions
Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
Interventions
risperidone, olanzapine, aripiprazole
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 18 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)

NCT00053703
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Olanzapine (enrollment closed in this treatment), Molindone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
8 Years to 19 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Medford, Massachusetts • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 4 Interventional

The Effects of Risperidone and Olanzapine on Thinking

NCT00108368
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Risperidone, Olanzapine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, aripiprazole, olanzapine, risperidone
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 2, 2026, 1:01 AM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 2, 2026, 1:01 AM EDT
Terminated Phase 4 Interventional

An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

NCT05741502
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Clozapine, Antipsychotics,Other (non-Clozapine)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 4 Interventional

Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder

NCT00181935
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
risperidone (Risperdal), olanzapine (Zyprexa)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
4 Years to 6 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 2, 2026, 1:01 AM EDT
Completed Phase 3 Interventional

Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay

NCT00065273
View directory record Official record
Conditions
Mental Retardation, Developmental Delay Disorder
Interventions
risperidone, clozapine, olanzapine
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Lawrence, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 1:01 AM EDT